Algernon Pharmaceuticals has announced that its Phase 2 trial of oral NP-120 (ifenprodil) in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) has reached 50% of its enrollment target. The proof-of-concept and open-label study (NCT04318704), currently underway at four sites in Australia and two in New…
Magnesium lithospermate B, a compound found in a traditional Chinese medicinal herb, eased several features of pulmonary fibrosis (PF) in a mouse model of the disorder. According to investigators, the anti-fibrotic effects of this plant compound were comparable to those of Esbriet (pirfenidone), an approved treatment for…
In a move that refocuses its clinical pipeline, Galapagos is discontinuing the development of GLPG1205, its experimental therapy for idiopathic pulmonary fibrosis (IPF), and advancing its most recent IPF candidate, GLPG4617, into a Phase 2 clinical trial. These and other decisions toward a “more risk-balanced pipeline” are…
Vicore Pharma and Alex Therapeutics are collaborating to develop a new phone app that could help improve the mental health of people with idiopathic pulmonary fibrosis (IPF). Vicore will own all rights to the new clinical program, called VP04, in exchange for various payments and royalties to…
Former New York Yankee and Grammy-nominated musician Bernie Williams will join musician, actress, and producer Queen Latifah, music duo The Bacon Brothers, singer-composer Paul Shaffer, and others to serve as a judge in the Breathless Ballad Challenge, a lyric competition that aims to raise awareness about idiopathic pulmonary…
If I could give strangers one gift, it would be that they never take their healthy lungs for granted. I’ve longed for a life with fully functioning lungs for 1,854 consecutive days. That’s how long it’s been since I was diagnosed with idiopathic pulmonary fibrosis (IPF) at the age of…
Last June, my parents and I stayed in a house in San Francisco while my mom, Diana, recovered from a single-lung transplant. Note that this was 2020 — the year of COVID-19. Because I was…
The U.S. Food and Drug Administration (FDA) granted fast track status to IM156, ImmunoMet Therapeutics’ treatment candidate for idiopathic pulmonary fibrosis (IPF). “Fast track designation is another important milestone for ImmunoMet with the potential to speed our ability to advance IM156 to patients,” Benjamin Cowen PhD, ImmunoMet’s CEO,…
Note: This article was updated to include information from a Hopkins study published on May 5, 2021, of responses after a second vaccine dose was given to transplant patients. Long before COVID-19 changed the world, organ transplant recipients were wearing masks to shield themselves from airborne threats.
Scientists discovered that blocking a tiny RNA molecule can help rejuvenate aged mesenchymal stem cells (MSCs) — which have the ability to give rise to specialized cells — derived from people with idiopathic pulmonary fibrosis (IPF). Those rejuvenated stem cells were found to have improved therapeutic efficacy when used…
Get regular updates to your inbox.
